Home > Journals > Minerva Respiratory Medicine > Past Issues > Minerva Respiratory Medicine 2021 December;60(4) > Minerva Respiratory Medicine 2021 December;60(4):136-41

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Respiratory Medicine 2021 December;60(4):136-41

DOI: 10.23736/S2784-8477.21.01921-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

COVID-19 vaccines: challenges and solutions

Zeinab MOHSENI AFSHAR 1, Arefeh BABAZADEH 2, Alireza JANBAKHSH 1, Mandana AFSHARIAN 1, Soheil EBRAHIMPOUR 2

1 Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran



Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.


KEY WORDS: SARS-CoV-2; COVID-19; Vaccines

top of page